PharVision Advisers’s INmune Bio INMB Stock Holding History

PharVision Advisers’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17,241	Closed	-$135K	–	352
2025 Q1	$135K	Buy	+17,241	New	+$137K	0.19%	235

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

PharVision Advisers's INMB Position: Q2 2025 in Review

PharVision Advisers sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 17,241 shares — an estimated $135K sold.

PharVision Advisers first reported a position in INMB in Q1 2025 and held it in 1 quarter. The position peaked at $135K in Q1 2025. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

PharVision Advisers reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 17,241 INmune Bio shares in Q2 2025, an estimated $135K.
PharVision Advisers first reported a position in INmune Bio in Q1 2025 and held it in 1 quarter.
PharVision Advisers's INmune Bio position peaked at $135K in Q1 2025.
79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.